Atlas Trials

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Clinical trial NCT06647732 · RECRUITING

Trial details

NCT number
NCT06647732
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Start date
2024-10-30
Primary completion
2028-08-31
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.